CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Total revenues	$ 6,217	$ 5,143	$ 12,640	$ 10,691
Costs and expenses:
Cost of goods sold	1,390	1,064	2,751	2,033
Research and development expenses	1,134	1,299	2,189	2,303
Acquired in-process research and development expenses	96	4,524	158	4,621
Selling, general and administrative expenses	1,351	1,239	2,406	2,315
Total costs and expenses	3,971	8,126	7,504	11,272
Income (loss) from operations	2,246	(2,983)	5,136	(581)
Interest expense	(256)	(240)	(513)	(481)
Other income (expense), net	(173)	250	(542)	92
Income (loss) before income taxes	1,817	(2,973)	4,081	(970)
Income tax expense	(300)	(373)	(842)	(838)
Net income (loss)	1,517	(3,346)	3,239	(1,808)
Net loss attributable to noncontrolling interest	5	7	12	20
Net income (loss) attributable to Gilead	$ 1,522	$ (3,339)	$ 3,251	$ (1,788)
Net income (loss) per share attributable to Gilead common stockholders - basic (in dollars per share)	$ 1.21	$ (2.66)	$ 2.59	$ (1.42)
Shares used in per share calculation - basic (in shares)	1,255	1,255	1,256	1,258
Net income (loss) per share attributable to Gilead common stockholders - diluted (in dollars per share)	$ 1.21	$ (2.66)	$ 2.58	$ (1.42)
Shares used in per share calculation - diluted (in shares)	1,260	1,255	1,261	1,258
Product sales
Revenues:
Total revenues	$ 6,152	$ 5,067	$ 12,492	$ 10,534
Royalty, contract and other revenues
Revenues:
Total revenues	$ 65	$ 76	$ 148	$ 157